{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:04:19Z","timestamp":1769162659102,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.ijantimicag.2007.06.005","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T11:10:45Z","timestamp":1185275445000},"page":"452-457","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004"],"prefix":"10.1016","volume":"30","author":[{"given":"Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2007.06.005_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.09.001","article-title":"Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002","volume":"51","author":"Wang","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2005.04.004","article-title":"Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia\u2013Pacific region (SENTRY 1998\u20132002)","volume":"52","author":"Hirakata","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.diagmicrobio.2005.10.004","article-title":"Making the most of surveillance studies: summary of the OPTAMA Program","volume":"53","author":"Kuti","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1592\/phco.27.3.333","article-title":"Pharmacodynamic target attainment of six \u03b2-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004","volume":"27","author":"DeRyke","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib7","first-page":"161","article-title":"Pharmacokinetics of meropenem single dose intravenous in healthy volunteers","volume":"20","author":"Zhao","year":"2004","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib8","first-page":"391","article-title":"Pharmacokinetics of imipenem in burned patients","volume":"6","author":"Wang","year":"2001","journal-title":"Xinan Guofang Yiyao"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib9","first-page":"385","article-title":"The pharmacokinetics of ceftazidime in burned patients","volume":"10","author":"Zong","year":"1994","journal-title":"Zhonghua Zhengxing Shangshao Waike Zazhi"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib10","first-page":"75","article-title":"Pharmacokinetics of intravenously administered cefoperazone\/sulbactam in normal volunteers","volume":"9","author":"Zhang","year":"2000","journal-title":"Chin J Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib11","first-page":"195","article-title":"Clinical pharmacokinetic study on cephalosporins and the proposed therapeutic regimens","volume":"13","author":"Zhang","year":"1995","journal-title":"Zhongguo Chuanranbing Zazhi"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib12","first-page":"25","article-title":"Comparison of pharmacokinetics of domestic and imported ciprofloxacin injection in healthy volunteers","volume":"6","author":"Tan","year":"1995","journal-title":"Zhongguo Yaofang"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijantimicag.2006.07.014","article-title":"Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals","volume":"28","author":"Ludwig","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.06.005_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin\u2013tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T21:54:48Z","timestamp":1546725288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857907002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0924857907002725"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.06.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}